Patents by Inventor Bryan Patrick MCKIBBEN

Bryan Patrick MCKIBBEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20210009567
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: July 23, 2020
    Publication date: January 14, 2021
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20200055843
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: August 29, 2019
    Publication date: February 20, 2020
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20190092759
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: September 21, 2018
    Publication date: March 28, 2019
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Substituted benzamides as RIPK2 inhibitors
    Patent number: 10138222
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1—, R2—, X, Y, and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: November 27, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Jianwen Cui, Donghong Amy Gao, Pingrong Liu, Bryan Patrick McKibben, Craig Andrew Miller, Hossein Razavi, Elizabeth Spencer, Sabine Ruppel, Anil K. Padyana
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180222893
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: April 9, 2018
    Publication date: August 9, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9975882
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 22, 2018
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • PYRIDINE AND PYRAZINE COMPOUNDS AS INHIBITORS OF RIPK2
    Publication number: 20180072703
    Abstract: The present invention relates to compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein R1, R2, X, Y, and HET are as defined herein.
    Type: Application
    Filed: September 6, 2017
    Publication date: March 15, 2018
    Inventors: Jianwen CUI, Donghong Amy GAO, Pingrong LIU, Bryan Patrick McKIBBEN, Craig Andrew MILLER, Hossein RAZAVI, Elizabeth SPENCER
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20180030037
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: October 12, 2017
    Publication date: February 1, 2018
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ
  • Heteroaromatic compounds as BTK inhibitors
    Patent number: 9815822
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 14, 2017
    Assignee: Boehringer Ingelheim Internatinal GmbH
    Inventors: Todd Bosanac, Joerg Bentzien, Michael Jason Burke, Ryan Michael Fryer, Eric Thomas Larson, Wang Mao, Bryan Patrick McKibben, Yue Shen, Fariba Soleymanzadeh, Matt Aaron Tschantz
  • HETEROAROMATIC COMPOUNDS AS BTK INHIBITORS
    Publication number: 20170174663
    Abstract: The present invention encompasses compounds of the formula (I) wherein the groups R1, Cy and Y are defined herein, which are suitable for the treatment of diseases related to BTK, and processes for making these compounds, pharmaceutical preparations containing these compounds, and their methods of use.
    Type: Application
    Filed: December 15, 2016
    Publication date: June 22, 2017
    Inventors: Todd BOSANAC, Joerg BENTZIEN, Michael Jason BURKE, Ryan Michael FRYER, Eric Thomas LARSON, Wang MAO, Bryan Patrick MCKIBBEN, Yue SHEN, Fariba SOLEYMANZADEH, Matt Aaron TSCHANTZ